Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Appointment:
Topics:
Countries:
Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Publications
-
Vasudevan L, Porter RM, Stinnett SS, Hart L, Turner EL, Zullig LL, et al. Perceived feasibility of a multicomponent prenatal intervention on childhood vaccinations: Findings from a national cross-sectional survey of prenatal care providers, April-June 2022. Int J Gynaecol Obstet. 2025 Mar 27;Hegmann TE, Walter EB, Smith MJ, Campbell J, El Sahly HM, Whitaker JA, et al. A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age. Vaccine. 2025 Mar 18;54:126991.Vasudevan L, Wang Y, Ostermann J, Yelverton V, Yang J, Fish LJ, et al. Rural-urban disparities in human papillomavirus vaccination: Findings from a cross-sectional survey of 13 southern US states, December 2019-January 2020. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association. 2025 Mar;41(2):e12913.Greenberg RG, Rountree W, Staat MA, Schlaudecker EP, Poindexter B, Trembath A, et al. Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2025 Mar 1;179(3):246–54.
See more publications at Scholars@Duke